Trademark Attorney / Law Firm
William F. Kruse – Trademark Portfolio
William F. Kruse specializes in Class 5 (Pharmaceuticals) trademark filings before the United States Patent and Trademark Office (USPTO), with 14 of 21 total filings concentrated in this category. The practice also covers Class 1 (Chemicals) along with 4 other Nice Classification classes. Filing activity spans from 2010 to 2019. Currently, 13 trademarks are registered.
Showing of trademarks Trademarks
Practice Areas by Trademark Class
William F. Kruse's trademark practice covers 4 Nice Classification classes, representing the range of industries and goods/services handled in their USPTO filings.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademark applications has William F. Kruse filed?
William F. Kruse has filed 21 trademark applications with the United States Patent and Trademark Office (USPTO). Of these, 13 registered, 5 abandoned, 3 cancelled.
What trademark classes does William F. Kruse specialize in?
William F. Kruse has filed trademarks across 4 Nice Classification classes. The most common practice areas include Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
How long has William F. Kruse been filing trademarks?
William F. Kruse's trademark filing history with the USPTO spans from 2010 to 2019, covering 9 years of trademark practice. During this period, William F. Kruse has handled 21 trademark applications.
What is William F. Kruse's trademark registration success rate?
William F. Kruse has a 62% trademark registration rate, with 13 out of 21 resolved applications resulting in successful registration. Currently, 0 applications are pending review.